HCP Education, Training & Support
With grateful thanks to our sponsor
DermaPro is the first 3D calculator for dermatologists to calculate the severity and extent of psoriasis known as the PASI score.
Previously, HCPs estimated the % psoriasis coverage based on their visual observations, but DermaPro calculates coverage based on the area “painted” onto a 3D model—a novel and intuitive solution that helps inexperienced dermatologists accurately calculate PASI scores.
Specifically designed to make it easy to input data via smartphones, DermaPro allows doctors to move around the patient while transposing what they observe directly onto the 3D model; increasing precision of measurement.
Judges Comments
With outstanding results, the DermaPro PASI Calculator is an innovative and genuinely useful tool to help aid and educate HCPs with a clear supportive connection that patients can also appreciate and benefit from. Being evidence-based and offering a practical solution to a clear unmet need, the judges found the campaign most admirable for its support of HCPs across all levels—and loved that it actively improves primary care practice through repeated usage.
DermaPro additionally stood out to the panel for its clear and concise approach to personalised learning, with the judges noting that the ability for HCPs to engage with the diagnostic experience led to campaign success underpinned by a series of strong qualitative and quantitative measures. Finally, the tool’s simplicity and adaptability maximises its impact and, in turn, improves patient outcomes in dermatology – effectiveness that speaks for itself.
Helen Clinton, Global Marketing Director, Uro-Oncology, Ipsen
Global Pain Awareness Week is an enduring, non-promotional, educational series of webinars in the pain community’s calendar. Developed by experts, for experts, it provides relevant, meaningful and in-demand content to HCPs to benefit patients.
In 2023 the training programme focused on impacting the standards of care for people living with pain, covering inclusivity of underrepresented patient populations, and trends in reported pain behaviour, to enable more open and compassionate conversations with patients. Through its global digital-and-hybrid reach, delegate-reported data demonstrated up to 2.3 million patients worldwide benefitting from Global Pain Awareness Week 2023.
The Theramex Menopause Mentoring Programme is an innovative digital initiative, that unites expert clinicians and HCPs from across the UK for tailored menopause mentoring.
The online programme facilitates small group informal mentoring and 1:1 sessions designed to increase HCP confidence in menopause diagnosis and management, identifying appropriate treatment and managing patient questions. Through interactive workbooks and web-based supporting materials, HCPs are empowered to learn flexibly around their busy schedules, enhancing accessibility and convenience.
The programme has proven extremely successful, exceeding all targets and receiving incredibly positive feedback. 100% of mentees reported increased knowledge in menopause diagnosis and management following mentoring.
In partnership with Sobi, we developed the Joint Health InSight tool to increase prioritisation of long-term joint health among haematologists.
Using a combination of interactive 3D models, detailed animations, medical scans from real patients, and informative text hotspots, Joint Health InSight visualised the often-invisible process of joint damage. This unbranded tool, directed at haematologists, was accessible on both desktop and tablet devices, enabling them to use it to support conversations with their patients.
Launched globally, the tool has been adopted in over 20 markets, received positive feedback from healthcare professionals, and been featured in prominent haematology congresses and scientific publications.
This campaign delivers truly omnichannel reach to pan-European MS HCPs, combining SEM, YouTube, LinkedIn, G-Med, Medscape, MS/neurology journals, programmatic, emails, native-ads and DOOH to drive audiences to an online educational website.
The campaign has greatly increased the number of HCPs with greater awareness and understanding of smouldering neuroinflammation, with 39,000+ site visits and ~2mins average dwell time for <$46 per engaged visit.
HCPs have reported verbal recognition and appreciation of the distinctive campaign and LinkedIn has described it as having “some of the most impactful and successful creatives of any healthcare industry campaign” they have seen.
In 2022, an estimated 80% of second-line diffuse large B-cell lymphoma patients were eligible for CAR T-cell therapy, but only 16% received it; many patients who could be benefiting from this curative treatment were not receiving it.
The Cell Therapy Hub is the centre of an international ecosystem for HCPs outside of the US. We set out to transcend the current standard of medical education and deliver individual learning experiences that resonate.
It’s great to be able to say that we are changing perceptions, influencing clinical practice and transforming patient lives.
Consumers assume shingles won’t affect healthy and active people. Even doctors may think so, as many don’t prioritise shingles prevention. But how can it be old news when it still affects one in three adults in their lifetime and may cause pain for weeks, months, or even years?
GSK, a global biopharma company, wanted to inject new life into the conversation about shingles. Introducing Albert, the world’s first humanoid installed with the varicella-zoster virus. Harnessing state-of-the-art technology, Albert engages HCPs with tailored educational content. His multilingual capability made him an ideal spokesperson, boosting awareness of the urgent need for prevention.
BioZone is an insights-based educational platform designed to increase neurologists’ confidence and familiarity with biosimilar medicines. Hosted on the Wolters Kluwer “FocusOn Neurology” platform, BioZone features innovative interactive quizzes, short-form videos, whiteboard animations, storytelling assets, and infographics. A comprehensive media campaign was launched across the EU and the US to reach neurologists, utilising third-party scientific websites, email deployments, banner ads, and paid search.
This multi-channel approach engaged over 9,000 healthcare professionals across more than 30 countries, greatly improving biosimilar awareness. As a result, neurologists’ confidence in prescribing biosimilar medicines increased by 67% within 12 months, ultimately improving patients’ access to treatment.
